• #LGM Pharma is a Belinostat CAS# 414864-00-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 414864-00-9
  • AHFC code:
  • Synonyms: Beleodaq, Belinostat, N-Hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide, PDX101, PX 105684, PXD-101, PXD101, UNII-F4H96P17NZ, Systematic Names, 2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide
  • ATC Code:
  • Chemical Formula: C15-H14-N2-O4-S
  • Molecular Weight: 318.3516
  • Assay/Purity: Typically NLT 98%
  • DrugBank:
  • SMILES: c1ccc(cc1)NS(=O)(=O)c2cccc(c2)/C=C/C(=O)NO
  • InChl: 1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
  • PubChem:
  • IUPAC:

Additional Details

Mode of Action:
PXD101 is a small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, and is currently being evaluated in a Phase II clinical trial for the treatment of multiple myeloma. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents. PXD101 may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. It may also make tumor cells more sensitive to other anticancer drugs. PXD101 is a type of histone deacetylase (HDAC) inhibitor and angiogenesis inhibitor. Preclinical data showing PXD101 down-regulation of thymidylate synthase (TS), an in vivo target of 5-fluorouracil (5-FU) provide a rationale for combination of PXD101 with 5-FU.
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials